CBSC activates China manufacturing pipeline and advances MyCardia AT into final NMPA submission phase with Ebulent Medical.

心脏生物科技解决方案激活MyCardia AT中国生产流程并进入NMPA最终申报阶段

CBSC activates China manufacturing pipeline and enters final NMPA submission phase for MyCardia AT cardiac monitoring device.

完成资产购买协议并启动心电图监测业务

An experienced executive management team is leading the way in the FDA and CE-cleared cardiac monitoring products and services arena, using smart phones and cloud-based software technology.

How can we help you?

Tell us what you are interested in.

订阅我们的新闻邮件!

订阅我们的电子报,我们将直接向您发送最新消息。